Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10305328 | 0.95 | CA12 (0.55) | SLC7A5TAAR1SLC6A2CA12CA1 | |
| SCHEMBL4399614 | 0.87 | SLC7A5 (0.51) | SLC7A5CA12CA1CA2CA9 | |
| SCHEMBL15828913 | 0.87 | SLC7A5 (0.47) | SLC7A5CA12CA1CA2CA9 | |
| SCHEMBL20038787 | 0.84 | SLC7A5 (0.49) | SLC7A5CA12CA1CA2CA9 | |
| SCHEMBL21690434 | 0.84 | SLC7A5 (0.71) | SLC7A5CA12CA1CA2CA9 | |
| SCHEMBL2617199 | 0.84 | SLC7A5 (0.71) | SLC7A5CA12CA1CA2CA9 | |
| SCHEMBL15876043 | 0.84 | SLC7A5 (0.56) | SLC7A5CA12CA1CA2CA9 | |
| SCHEMBL2617129 | 0.84 | SLC7A5 (0.71) | SLC7A5CA12CA1CA2CA9 | |
| SCHEMBL28220739 | 0.84 | SLC7A5 (0.56) | SLC7A5CA12CA1CA2CA9 | |
| SCHEMBL422913 | 0.83 | LOXL2 (0.65) | SLC7A5CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8343928-B2 | Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus | SEATTLE GENETICS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-7973044-B2 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-7968547-B2 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-20100160343-A1 | HETEROARYL, HETEROCYCLIC AND ARYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. | 2010-06-24 | — | — | US | disclosed |
| US-20100160341-A1 | HETEROARYL, HETEROCYCLIC AND ARYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. | 2010-06-24 | — | — | US | disclosed |
| US-7741328-B2 | Treating inflammatory diseases such as rheumatoid arthritis, multiple sclerosis or Crohn's disease; Very Late Antigen-4 (VLA-4), also called alpha 4 beta 1 integrin; N-(sulfonamido-substituted pyrimidyl, pyridyl or pyrazyl)-L-4-(N,N-dimethylcarbamyloxy)phenylalanine compounds | ELAN PHARMACEUTICALS, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| EP-1144388-B1 | ACYL DERIVATIVES WHICH TREAT VLA-4 RELATED DISORDERS | ELAN PHARM INC (US) | 2010-01-13 | — | — | EP | disclosed |
| US-7605166-B2 | Synergistic mixture of methotrexate and integrin antigen or antibody | ELAN PHARMACEUTICALS INC. (US) | 2009-10-20 | — | — | US | disclosed |
| EP-1635822-A4 | METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS | ELAN PHARM INC (US) | 2009-06-24 | — | — | EP | disclosed |
| US-7378529-B2 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | WYETH (US) | 2008-05-27 | — | — | US | disclosed |
| WO-2005000246-A2 | METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS | ELAN PHARMACEUTICALS, INC. (US) | 2005-01-06 | — | — | WO | disclosed |
| US-20040147512-A1 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | disclosed |
| CN-1119340-C | Carbamoyloxy compounds that inhibit VLA-4 mediated leukocyte adhesion | ELAND PHARMACEUTICALS CO (US) | 2003-08-27 | — | — | CN | disclosed |
| US-20030139402-A1 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated byVLA-4 | KONRADI ANDREI W (US) | 2003-07-24 | — | — | US | disclosed |
| US-20030125324-A1 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | KONRADI ANDREI W (US) | 2003-07-03 | — | — | US | disclosed |
| US-6492372-B1 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. | 2002-12-10 | — | — | US | disclosed |
| CN-1351592-A | Acyl derivatives for the treatment of VLA-4 related diseases | ELAN PHARM INC (US) | 2002-05-29 | — | — | CN | disclosed |
| EP-1144388-A1 | ACYL DERIVATIVES WHICH TREAT VLA-4 RELATED DISORDERS | Elan Pharmaceuticals, Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| CN-1265657-A | Carbamoyloxy compounds that inhibit VLA-4 mediated leukocyte adhesion | ELAND PHARMACEUTICALS CO (US) | 2000-09-06 | — | — | CN | disclosed |
| WO-2000043372-A1 | ACYL DERIVATIVES WHICH TREAT VLA-4 RELATED DISORDERS | ELAN PHARMACEUTICALS, INC. (US) | 2000-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139402-A1 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated byVLA-4 | VCAM1, ICAM1, ITGB4 | SLC7A5 3199/4885TAAR1 3225/4885SLC6A2 2327/4885 |
| US-20100160341-A1 | HETEROARYL, HETEROCYCLIC AND ARYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | VCAM1, ICAM1, ITGB4 | SLC7A5 2959/4885TAAR1 2717/4885SLC6A2 2290/4885 |
| US-20030125324-A1 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, ITGB4 | SLC7A5 2959/4885TAAR1 2717/4885SLC6A2 2290/4885 |
| US-20040147512-A1 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, ITGB4 | SLC7A5 2959/4885TAAR1 2717/4885SLC6A2 2290/4885 |
| US-20100160343-A1 | HETEROARYL, HETEROCYCLIC AND ARYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | VCAM1, ICAM1, ITGB4 | SLC7A5 2959/4885TAAR1 2717/4885SLC6A2 2290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.